Prospective multicentre clinical performance evaluation of second and third generation zotarolimus-eluting stents to treat patients with bifurcated coronary lesions
| Autor: | Cecilia Fantoni, Carlo Trani, Maurizio Turturo, Maria De Vita, Azeem Latib, Francesco Summaria, Francesco Burzotta, Stefano Benedetto, Alessandro Manzoli, Claudio Larosa |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Target lesion
medicine.medical_specialty business.industry medicine.medical_treatment Hazard ratio Percutaneous coronary intervention Stent General Medicine 030204 cardiovascular system & hematology Confidence interval Surgery 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure medicine Radiology Nuclear Medicine and imaging Zotarolimus cardiovascular diseases 030212 general & internal medicine Radiology Cardiology and Cardiovascular Medicine business Mace medicine.drug Artery |
| Zdroj: | Catheterization and Cardiovascular Interventions. 87:15-22 |
| ISSN: | 1522-1946 |
| DOI: | 10.1002/ccd.25954 |
| Popis: | Aim To assess the “real world” clinical outcome of patients with bifurcated lesions undergoing percutaneous coronary intervention with implantation of second and third generations of zotarolimus-eluting stent. Methods and Results Nine Italian centres participated in a prospective multicentre clinical project evaluating the outcome of patients receiving zotarolimus-eluting Resolute stent and Resolute Integrity stents. Patients with bifurcated lesions entered this evaluation. Clinical characteristics and angiographic and procedural details were prospectively recorded. Clinical outcome was prospectively assessed to evaluate the occurrence of major adverse cardiac events (MACE). A total of 577 patients were enrolled. The target lesion was distal left main in 11.1% and left anterior descending artery in 52.8%, and 30.3% of lesions were Medina 1,1,1. At a mean follow-up time of 27.0 ± 13.5 months, the survival free from MACE was 91.8%. Survival free from MACE was similar in patients grouped according to different bifurcated lesion complexity. On the contrary, patients receiving a single stent had better survival free from MACE as compared with those with double stent (P = 0.005). At multivariable analysis, double stenting (but not bifurcated lesion complexity) was found to be a significant predictor of MACE (hazard ratio, 2.52; 95% confidence interval, 1.28–4.94; P = 0.007). Of note, patients receiving the second stent as a bail-out had worse survival free from MACE compared with those who received it as a planned technique (P = 0.045). Conclusion The treatment of patients with bifurcated lesions with second and third generation zotarolimus-eluting stents is associated with good long-term clinical outcomes. Clinical outcome seems to be independent of lesion complexity, but may be influenced by the stenting technique (single or double stenting as well as elective or bail-out double stenting). © 2015 Wiley Periodicals, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text